Status:
COMPLETED
Ivermectin Role in Covid-19 Clinical Trial
Lead Sponsor:
Elaraby Hospital
Collaborating Sponsors:
Shebin El-Kom Teaching Hospital
Conditions:
Covid19
Eligibility:
All Genders
18+ years
Phase:
PHASE4
Brief Summary
Because ivermectin is being used to treat COVID-19 with insufficient evidence, the investigator conducted a randomized clinical trial to investigate the efficacy and safety of ivermectin in comparison...
Detailed Description
This study is an adaptive, randomized, double-blinded, controlled trial to evaluate the safety and efficacy of therapeutic agents in hospitalized adult patients diagnosed with COVID-19. The study is a...
Eligibility Criteria
Inclusion
- Subject (or legally authorized representative) provides written informed consent prior to initiation of any study procedures.
- Understands and agrees to comply with planned study procedures.
- Agrees to the collection of OP swabs and venous blood per protocol.
- Male or non-pregnant female adult ≥18 years of age at time of enrollment.
- Has laboratory-confirmed SARS-CoV-2 infection as determined by PCR, or other
- Severe cases according to WHO definition.
Exclusion
- ALT/AST \> 5 times the upper limit of normal.
- Mortality within 12 hours of admission.
- Pregnancy.
- Anticipated transfer to another hospital within 24 hours.
- Allergy to any study medication commercial or public health assay in any specimen prior to randomization.
- Mechanically ventilated on admission
Key Trial Info
Start Date :
December 6 2020
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
February 6 2021
Estimated Enrollment :
300 Patients enrolled
Trial Details
Trial ID
NCT04746365
Start Date
December 6 2020
End Date
February 6 2021
Last Update
February 9 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Shebin-Elkom teaching hospital
Shibīn al Kawm, Menoufia, Egypt